GoAI
Get started
Spectral AI, Inc. logo

Spectral AI, Inc.

MDAI

NASDAQHealthcareMedical - Specialties

Open in GoAI

Previous close

$1.60

+$0.03 · +1.91%

Aug 21, 4:00 PM ET

Pre-market

$1.57

−$0.03 · -1.88%

Aug 24, 7:07 AM ET

MDAI company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

43

Fair Value

Momentum

29

Weakening

Sentiment

61

Bullish

Risk resilience

36

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation; and delivers a binary prediction on the wounds capacity to heal or not heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient’s wounds. Its system also includes MSI imaging technology, which consists of proprietary multi-spectral optics and sensors that capture injured tissue images; and AI-Burn software. Spectral AI, Inc. is headquartered in Dallas, Texas.

Industry
Medical - Specialties
Sector
Healthcare
Headquarters
US
CEO
Vincent S. Capone
Listed since
Apr 6, 2021
Employees
65

Market position

Day range

Current $1.60

52-week range

Current $1.60

Open
$1.57
Previous close
$1.57
Volume
138.61K
0.29× average
Average volume
477.2K
Average daily volume
Market cap
50.92M USD
Beta
1.18
Market reference 1
50-day average
$1.6886
-5.25% below average
200-day average
$1.7027
-6.03% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
32.36M USD
EV / EBITDA
-5.97×
Earnings yield
-20.11%
Free cash flow yield
-26.34%

Profitability & efficiency

Return on equity
132.20%
Return on assets
-35.37%
Return on invested capital
-197.00%

Financial health

Current ratio
0.94×
Altman Z-score
-4.45
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends62%-2%-67%-132%Gross margin, FY2021: 46.28%Gross margin, FY2022: 42.72%Gross margin, FY2023: 43.64%Gross margin, FY2024: 44.87%Gross margin, FY2025: 45.42%Operating margin, FY2021: -27.42%Operating margin, FY2022: -10.43%Operating margin, FY2023: -71.91%Operating margin, FY2024: -22.25%Operating margin, FY2025: -43.78%Net margin, FY2021: -26.17%Net margin, FY2022: -11.48%Net margin, FY2023: -115.50%Net margin, FY2024: -51.77%Net margin, FY2025: -38.53%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 46.28%. Gross margin FY2022 42.72%. Gross margin FY2023 43.64%. Gross margin FY2024 44.87%. Gross margin FY2025 45.42%. Operating margin FY2021 -27.42%. Operating margin FY2022 -10.43%. Operating margin FY2023 -71.91%. Operating margin FY2024 -22.25%. Operating margin FY2025 -43.78%. Net margin FY2021 -26.17%. Net margin FY2022 -11.48%. Net margin FY2023 -115.50%. Net margin FY2024 -51.77%. Net margin FY2025 -38.53%.

Income trends

Revenue

19.65M USD-33.57%

Operating income

−8.6M USD-30.70%

Net income

−7.57M USD+50.56%
Income trends across reported periods34.62M USD14.45M USD−5.72M USD−25.9M USDRevenue, FY2021: 15.24M USDRevenue, FY2022: 25.37M USDRevenue, FY2023: 18.06M USDRevenue, FY2024: 29.58M USDRevenue, FY2025: 19.65M USDOperating income, FY2021: −4.18M USDOperating income, FY2022: −2.65M USDOperating income, FY2023: −12.98M USDOperating income, FY2024: −6.58M USDOperating income, FY2025: −8.6M USDNet income, FY2021: −3.99M USDNet income, FY2022: −2.91M USDNet income, FY2023: −20.85M USDNet income, FY2024: −15.32M USDNet income, FY2025: −7.57M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 15.24M USD. Revenue FY2022 25.37M USD. Revenue FY2023 18.06M USD. Revenue FY2024 29.58M USD. Revenue FY2025 19.65M USD. Operating income FY2021 −4.18M USD. Operating income FY2022 −2.65M USD. Operating income FY2023 −12.98M USD. Operating income FY2024 −6.58M USD. Operating income FY2025 −8.6M USD. Net income FY2021 −3.99M USD. Net income FY2022 −2.91M USD. Net income FY2023 −20.85M USD. Net income FY2024 −15.32M USD. Net income FY2025 −7.57M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue19.65M USD29.58M USD18.06M USD25.37M USD15.24M USD
Cost of goods sold10.73M USD16.31M USD10.18M USD14.53M USD8.19M USD
Gross profit8.93M USD13.27M USD7.88M USD10.84M USD7.05M USD
Research and development19.65M USD29.58M USD———
Selling, general, and administrative17.53M USD19.86M USD20.86M USD13.48M USD11.23M USD
Operating expenses17.53M USD19.86M USD20.86M USD13.48M USD11.23M USD
Interest income−886K USD14K USD172K USD21K USD—
Interest expense1.51M USD2.97M USD———
Depreciation and amortization635K USD588K USD722K USD568K USD1K USD
Operating income−8.6M USD−6.58M USD−12.98M USD−2.65M USD−4.18M USD
Net income−7.57M USD−15.32M USD−20.85M USD−2.91M USD−3.99M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 4 misses, 2 met estimates
Average EPS surprise
-30.33%
11 comparable reports
Latest EPS result
-0.13
Estimate -0.14 · Beat by 3.70%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.15-0.05-0.25-0.45Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MetQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -0.41, estimate -0.13, surprise -215.38%, Miss. Q2 2025, reported May 14, 2025: actual 0.11, estimate -0.1, surprise +210.00%, Beat. Q3 2025, reported Aug 12, 2025: actual -0.31, estimate -0.07, surprise -342.86%, Miss. Q4 2025, reported Nov 11, 2025: actual -0.13, estimate -0.085, surprise -52.94%, Miss. Q1 2026, reported Mar 24, 2026: actual -0.11, estimate -0.12, surprise +8.33%, Beat. Q2 2026, reported May 12, 2026: actual -0.11, estimate -0.11, surprise 0.00%, Met estimate. Q3 2026, reported Aug 11, 2026: actual -0.13, estimate -0.135, surprise +3.70%, Beat. Q4 2026, reported Nov 10, 2026: actual —, estimate -0.14, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates7.98M6.16M4.35M2.53MQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual 7.6M USD, estimate 6.82M USD, surprise +11.43%, Beat. Q2 2025, reported May 14, 2025: actual 6.71M USD, estimate 5.44M USD, surprise +23.32%, Beat. Q3 2025, reported Aug 12, 2025: actual 5.07M USD, estimate 5.48M USD, surprise -7.65%, Miss. Q4 2025, reported Nov 11, 2025: actual 3.79M USD, estimate 5.06M USD, surprise -25.10%, Miss. Q1 2026, reported Mar 24, 2026: actual 3.85M USD, estimate 2.91M USD, surprise +32.43%, Beat. Q2 2026, reported May 12, 2026: actual 3.99M USD, estimate 4.13M USD, surprise -3.25%, Miss. Q3 2026, reported Aug 11, 2026: actual 3.52M USD, estimate 4.17M USD, surprise -15.45%, Miss. Q4 2026, reported Nov 10, 2026: actual —, estimate 5.33M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

2 institutions

MDAI peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding MDAI

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.14M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
383.63K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
146.29K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research MDAI

research.disclaimer